Contents

1 Introduction ................................................................. 1
2 Why Now the Need for a New Clinical Trials Model for Antidepressants? .................................................. 5
3 Reconceptualizing Depression, and the Current Scene on Dimensionality and the RDoC ................................. 9
   “Opposed Neurobehavioral States” ..................................... 11
   On Replacing Diagnosis with Dimensions: The Current Scene and the RDoC .................................................. 12
4 Aims and Basic Requirements of Clinical Trials: Conventional and Component-Specific Models .............................. 13
5 Methods for Measuring the Components and the Profile of Drug Actions: The Multivantaged Approach ..................... 17
6 Achieving the “Ideal” Clinical Trial: An Example of Applying the Merged Componential and Established Models ............ 21
   Applying the Models .......................................................... 22
   Measurement of Behavioral Components and Severity of Depressed State .................................................. 23
7 Comparing the Component-Specific Model Directly with the Established Diagnosis-Specific Trial .......................... 27
   Secondary Aims .............................................................. 27
8 Prediction and Shortening the Clinical Trial: Further Advantages of the Component-Specific Model ............................... 31
9 The Video Clinical Trial .................................................... 35
   Special Application in Multicenter Trials and Proof-of-Concept Studies .................................................. 37
10 Conclusions ..................................................................... 39
| Appendix I: Four Case Studies of Patients in Multivantage (MV) and Video Models of Clinical Trials: Instructions for Scoring MV Components and Dimensions and Video Measure Profiles | 41 |
| Appendix II: Operational Definitions of State Constructs and Global Outcome Measures | 51 |
| Appendix III: Composition and Scoring of Constructs, Dimensions and Overall Severity Measures | 53 |
| Appendix IV: MV Methods for Measuring Constructs and Outcome Dimensions, Brief Version for Outpatient Studies | 59 |
| References | 61 |
| Index | 65 |
Clinical Trials of Antidepressants
How Changing the Model Can Uncover New, More Effective Molecules
Katz, M.M.
2016, XV, 66 p. 3 illus. in color., Softcover
ISBN: 978-3-319-26463-9